際際滷

際際滷Share a Scribd company logo

Personalized medicine

Download as PPTX, PDF
S
Simrana Fathima

This document discusses dosage forms for personalized medicine. It introduces personalized medicine as tailoring medical treatment to individual patient characteristics. Personalized medicine relies on a patient's biology, DNA and RNA to help confirm diseases and identify the right drugs. It gives examples of how genetic testing can identify mutations in cancer patients that determine the most effective drug, and how metabolism rates can require adjusting drug doses between patients. The document advocates for dosage forms like minitablets, orodispersible tablets and opened capsules mixed with food to better suit individual patient needs based on their age, disease, genetics or physiology.

1 of 10
Download to read offline
DOSAGE FORM FOR PERSONALIZED MEDICINE M.SIMRANA FATHIMA (M.PHARMACY)
INTRODUCTION Personalized medicine is a multifaceted to patient care. risk assessment. Diagnosis, treatment, management. Offers right drug to to the right patient for the right disease at the right time with the right dosage. Relies on patients fundamental biology, DNA, RNA which helps in disease conformation.
Find defected DNA mutation Eg:breast cancer, patient A has HER2 protien (rare) Identify the drugs against mutation Trastuzumab supresses the protein and tumour. treatment The patient A is given TRASTUZUMAB
DEFINITION Individualized or precision medicine or genomi One size doesnt fit all Personalized medicine is the tailoring of medical treatment to the individual characteristics of each patient.
Categories of patient for personalized medicine
Age related eg paediatric patient TABLETS: bigger size , so broken into half CAPSULE: opened mixed/dissolved with food or liquids Loss of efficacy, irritation in stomach, improper dosing, bad taste. Minitablets Orodispersible dosage form.
Disease related - eg cancer ANTILEUKEMIA DRUG (6- mercaptopurine) Drug gets metabolized quickly so dose is increased Metabolise the drug slowly and need less dose Most normal people Other people metabolizes the drug poorly, so fatal, minimum dose Small portion Tpmt deficient Tpmt normal
Genetically determined susceptibility After chemotheraphy, patient A was taking erlotinib. But after 3 yrs the tumour wasnt at bay. The patient A underwent genetic testing which resulted ALK (anaplastic lymphoma kinase) positive. Patient A was prescribed with crizotinib which supresses the ALK positive lung cancer tumour. After the clinical trials the tumour was barely visible
Individual physiological status Similar to the other categories
Thank you

More Related Content

Personalized medicine

  • 1. DOSAGE FORM FOR PERSONALIZED MEDICINE M.SIMRANA FATHIMA (M.PHARMACY)
  • 2. INTRODUCTION Personalized medicine is a multifaceted to patient care. risk assessment. Diagnosis, treatment, management. Offers right drug to to the right patient for the right disease at the right time with the right dosage. Relies on patients fundamental biology, DNA, RNA which helps in disease conformation.
  • 3. Find defected DNA mutation Eg:breast cancer, patient A has HER2 protien (rare) Identify the drugs against mutation Trastuzumab supresses the protein and tumour. treatment The patient A is given TRASTUZUMAB
  • 4. DEFINITION Individualized or precision medicine or genomi One size doesnt fit all Personalized medicine is the tailoring of medical treatment to the individual characteristics of each patient.
  • 5. Categories of patient for personalized medicine
  • 6. Age related eg paediatric patient TABLETS: bigger size , so broken into half CAPSULE: opened mixed/dissolved with food or liquids Loss of efficacy, irritation in stomach, improper dosing, bad taste. Minitablets Orodispersible dosage form.
  • 7. Disease related - eg cancer ANTILEUKEMIA DRUG (6- mercaptopurine) Drug gets metabolized quickly so dose is increased Metabolise the drug slowly and need less dose Most normal people Other people metabolizes the drug poorly, so fatal, minimum dose Small portion Tpmt deficient Tpmt normal
  • 8. Genetically determined susceptibility After chemotheraphy, patient A was taking erlotinib. But after 3 yrs the tumour wasnt at bay. The patient A underwent genetic testing which resulted ALK (anaplastic lymphoma kinase) positive. Patient A was prescribed with crizotinib which supresses the ALK positive lung cancer tumour. After the clinical trials the tumour was barely visible
  • 9. Individual physiological status Similar to the other categories